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Abstract:  Corneal collagen cross-linking (CxL) is a prevalent surgical method for the management of keratoconus. 
However, literature suggests that, further to keratoconus, CxL has a beneficial impact on a series of corneal related 
diseases and states.  
This article attempts to provide a contemporary review for all additional applications of CxL. Specifically, it outlines the 
most recent studies that demonstrate the beneficial impact of CxL for iatrogenic ectasias, pellucid marginal degeneration, 
infectious keratitis, bullous keratitopathy, and for ulcerative keratitis.   
The outcome of this review indicates that CxL could serve as a primary or adjuvant therapeutic modality for all 
aforementioned corneal-related pathologic states. 
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INTRODUCTION 
  Corneal collagen cross linking is a minimally invasive 
technique that with the use of riboflavin and Ultraviolet – A 
irradiation can ensure the production of a stiffening effect 
capable of augmenting the rigidity of the corneal tissue. The 
interaction between riboflavin and UVA irradiation results in 
the formation of bonds between collagen fibrils in the 
corneal stroma, quasi “freezing” the cornea. The most 
common use of CXL is the management of ectatic disorders 
by halting their progression. Nevertheless, a continuous line 
of new applications is under investigation with promising 
results. 
CXL AFTER REFRACTIVE SURGERY 
  It is known that both LASIK and PRK modify corneal 
stability and overall tissue strength. Researchers suggested 
that regression after refractive surgery might be reduced by 
means of CXL. This treatment appears to be particularly 
applicable to patients who are suspected of having forme 
fruste keratoconus or those with a correction that exceeds -8 
D. These patients may benefit from stiffening of the cornea 
because keratectasia might not develop. 
  Early treatments of iatrogenic keratectasia after LASIK 
performed at the University of Dresden seem to be effective  
in preventing further progression of the post – refractive 
surgery ectasia. Hafezi et al. reported that CXL arrested 
and/or partially reversed keratectasia of 10 patients over a 
postoperative follow-up of up to 25 months as demonstrated 
by preoperative and postoperative corneal topography 
showing a reduction in maximum Keratometry readings [1]. 
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CXL IN PELLUCID MARGINAL DEGENERATION 
 Kymionis  et al. performed simultaneous photorefractive 
keratectomy and CXL in a 34-year-old woman with 
progressive pellucid marginal corneal degeneration in both 
eyes. 12 months postoperatively, BCVA improved from 
20/50 and 20/63 to 20/25 and 20/32 in the right and left eye, 
respectively. Corneal topography revealed significant 
improvement in both eyes [2]. 
CXL IN BULLOUS KERATOPATHY 
  CXL has been shown to have an antiedematous effect on 
the cornea. Wollensak et al. examined if this effect can be 
used for the treatment of bullous keratopathy [3]. This 
clinical interventional case series included 3 patients with 
bullous keratopathy due to pseudophakia, corneal transplant 
rejection and Fuchs’ endothelial dystrophy. Corneal 
thickness was reduced. The bullous changes of the 
epithelium were markedly improved, resulting in loss of pain 
and discomfort. Visual acuity was significantly improved in 
the case that did not present prior stromal scarring. In similar 
results concluded Krueger et al. who performed staged 
intrastromal delivery of riboflavin with UVA cross-linking 
in a case of advanced bullous keratopathy [4]. Despite the 
encouraging results, longer follow-up is necessary to confirm 
the long-term impact of CXL in bullous keratopathy. 
CXL IN INFECTIOUS KERATITIS 
  In 2008, Martins et al. [5] demonstrated the antimicrobial 
properties of CXL against common pathogens. A group of 
bacteria was tested: Pseudomonas aeruginosa (PA), 
Staphylococcus aureus (SA), Staphylococcus epidermidis 
(SE), methicillin-resistant S. aureus (MRSA), multidrug-
resistant P. aeruginosa (MDRPA), drug-resistant Strepto-
coccus pneumoniae (DRSP), and Candida albicans (CA). 
Riboflavin/UVA was effective against SA, SE, PA, MRSA, 
MDRPA, and DRSP, but was ineffective on CA. 18    The Open Ophthalmology Journal, 2011, Volume 5  Kozobolis et al. 
 Iseli  et al. [6] evaluated the efficacy of CXL for treating 
infectious melting keratitis. Five patients with infectious 
keratitis associated with corneal melting were treated with 
CXL. CXL was performed when the infection did not 
respond to systemic and topical antibiotic therapy. Follow-up 
after cross-linking ranged from 1 to 9 months. In all cases, 
the progression of corneal melting was halted after CXL 
treatment. Emergency keratoplasty was not necessary in any 
of the 5 cases presented. 
 Moreover,  Micelli-Ferrari  et al. [7] described a case of 
keratitis caused by the Gram-negative E. Coli treated with 
CXL with outstanding outcomes. 
CXL IN COMPLICATED BULLOUS KERATOPATHY 
WITH ULCERATIVE KERATITIS 
  CXL’s antimicrobial and anti-edematous properties were 
demonstrated by Kozobolis et al. [8] in their report of two 
patients with combined bullous keratopathy and ulcerative 
keratitis, resistant to conventional treatments. Both patients 
presented significant improvement of their vision-
threatening corneal ulcer, corneal edema and BCVA for a 
follow-up period of two months. 
CONCLUSION 
  CXL is a promising therapeutic intervention for corneal 
tissue stabilization in diseases that manifest with progressive 
keratectasia like keratoconus. Moreover, CXL anti-
edematous and antimicrobial properties were demonstrated 
in a series of studies suggesting its therapeutic indications in 
bullous keratopathy and in infectious keratitis as an adjuvant 
treatment to conventional therapeutic modalities. 
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